Brompheniramine / dextromethorphan / pseudoephedrine

psilodex.org/m/brompheniramine-dextromethorphan-pseudoephedrine · data v2026.10.02

Clinical contraindication: None listed; No clinical contraindication identified.
Best available evidence: Mechanism only
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: brompheniramine-dextromethorphan-pseudoephedrine · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Dextromethorphan is serotonergic and an NMDA antagonist (dissociative at high doses); pseudoephedrine can raise blood pressure and heart rate; brompheniramine is anticholinergic and sedating. Each component can add to psilocybin's effects on perception, mood or vital signs.

Human data with psilocybin: None known: no published human data with psilocybin

Evidence types on this record

ThMechanism only (theoretical)

02 Pharmacology relevant to psilocybin

5 listed · counted on reports

Serotonergic: Increases serotonin activity, for example by blocking its reuptake or releasing it. Psilocybin acts on serotonin receptors, so effects can add together. With antidepressant use, the psilocybin response can be weaker. Sources [2]
Dissociative (NMDA antagonist): Blocks NMDA receptors and can cause dissociation: feeling detached from the body or surroundings. Effects can add to psilocybin’s. Sources [3]
Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]
Anticholinergic: Blocks acetylcholine. Can cause a fast heart rate, dry mouth, reduced sweating and heat intolerance, and confusion, more so at high doses or in combination. Sources [1]
Sedating or CNS depressant: Slows the central nervous system: drowsiness, slower reactions and impaired coordination, and slowed breathing at high doses. Effects add with other sedating substances. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-02

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide Syrup · FDA label (DailyMed) — anticholinergic (drying) and sedative effects; additive with CNS depressants; caution in hypertension; adverse reactions include hypertension, palpitation, tachycardia; MAOI contraindication for dextromethorphan
Preston CL (ed). Stockley’s Drug Interactions, 11th ed. Pharmaceutical Press, 2016., p. 338
Auvelity (dextromethorphan–bupropion): §12.1 states dextromethorphan is an uncompetitive NMDA receptor antagonist · FDA label (DailyMed)

Record history

v2026.10.02First published.
2026-10-02Last reviewed against its sources.

Report an error in this record →